Hawaii’s “Ryan’s law” push raises a question Arizona patients know too well: Can you use medical cannabis where you receive care?

Feb 9

Ryan's law proposals, including Hawaii’s HB 1542, aim to let terminally ill patients and some older adults use medical cannabis in health care facilities with clear safeguards.

A terminally ill patient can have a medical cannabis card, a legal product and a physician’s recommendation, then still be told “not here” once they cross the threshold into a hospital, hospice home or skilled nursing facility. That gap is not theoretical. It shows up when pain spikes at 2 a.m., when nausea makes food impossible, or when a person at the end of life wants relief without feeling sedated and disconnected from loved ones.

Hawaii lawmakers are now testing whether state policy can close that gap.

In early February, Hawaii House committees advanced House Bill 1542, a “Compassionate Access to Medical Cannabis Act,” explicitly labeled “Ryan’s law,” aimed at allowing certain patients to use medical cannabis inside specified health care facilities under defined conditions.

The effort matters in Hawaii because it could give patients a clear path to use medical cannabis during some of the most vulnerable moments of their lives. It matters in Arizona because the same moral and legal tensions already play out here, especially in long-term care settings where policies differ from facility to facility. It also matters nationally because “Ryan’s law” has become shorthand for a wider push to treat medical cannabis as a comfort-care option rather than a contraband item in clinical spaces.

What Hawaii’s bill would actually do

HB 1542 is designed for a specific patient group. Under the bill text, a “patient” would be either terminally ill or a person over 65 with a chronic disease who has a written certification from a physician or advanced practice registered nurse under Hawaii’s medical cannabis program. The bill also defines “terminally ill” as a prognosis of one year or less if the disease follows its natural course.

The facilities covered are broader than many people assume. The bill defines “health care facility” to include general acute care hospitals, skilled nursing facilities, hospice homes, home health agencies and certain other licensed settings, then excludes chemical dependency recovery hospitals, state hospitals and emergency departments while a patient is receiving emergency services and care.

The heart of the proposal is the duty it places on facilities. As introduced, it says a covered facility “shall permit” patient use of medical cannabis, then layers in guardrails that read like a policy manual: no smoking or vaping, documentation in the patient’s record, proof of registration or written certification, locked storage, and a clear division of labor where the patient or primary caregiver is responsible for acquiring and administering the product. Facility staff are barred from administering medical cannabis or retrieving it from storage.

Those details are not window dressing. They speak directly to what health systems worry about: diversion, staff exposure, smoke-free laws, and the operational question of who touches the product, who documents it, and who is responsible if something goes wrong.

HB 1542 also includes a significant limitation: general acute care hospitals could not permit a patient over 65 with a chronic disease to use medical cannabis unless that patient is terminally ill.

That narrowing drew concern from advocates quoted in the committee process. Marijuana Policy Project supported access for terminally ill patients and “kupuna,” a Hawaiian term often used for elders, yet warned that the bill as drafted could restrict other patients who might currently be allowed to use medical cannabis depending on a facility’s policies.

Why “Ryan’s law” keeps appearing in statehouses

The phrase “Ryan’s law” comes from California’s path, where lawmakers moved to ensure certain terminally ill patients could use medical cannabis in covered facilities, often framed as a compassionate end-of-life issue. A 2025 peer-reviewed article describing implementation in an inpatient oncology setting notes that the intent is patient access to their own medical cannabis, without requiring the facility to provide the product.

The model has traveled. Marijuana Moment reported that at least 13 states were exploring some version of “Ryan’s law” legislation in 2026, including Hawaii and Arizona.

The shared premise is straightforward: if a state recognizes medical cannabis as lawful medicine for qualified patients, the right to use it should not disappear when care becomes more intensive or institutional.

The barriers, however, are also straightforward. Cannabis remains federally illegal, and hospitals and long-term care facilities live under a web of federal rules tied to Medicare and Medicaid participation, accreditation standards and controlled-substance compliance. A peer-reviewed policy paper on hospital considerations bluntly notes that institutions worry about legal and financial risk because cannabis is illegal under federal law and hospitals rely on federal funding mechanisms.

HB 1542 attempts to address that reality with an off-ramp: if a federal regulatory agency, the U.S. Department of Justice or the federal Centers for Medicare and Medicaid Services takes enforcement action or issues explicit prohibitions tied to a facility’s compliance with state medical cannabis rules, the facility may suspend compliance until it is cleared to resume.

That clause reflects the tightrope states are trying to walk. “Ryan’s law” bills typically try to protect the patient’s dignity without asking a nurse or pharmacist to break federal rules, stock cannabis, or place it into the hospital’s medication distribution system.

The medical context patients deserve to hear plainly

Medical cannabis is not a cure for terminal illness. Patients deserve clarity on that point, especially when online hype can blur the line between symptom support and disease treatment.

The strongest evidence base for cannabis and cannabinoids has historically centered on symptom domains: chronic pain, chemotherapy-induced nausea and vomiting, and certain multiple sclerosis spasticity symptoms. The National Academies’ landmark 2017 report summarized “substantial” or “conclusive” evidence in those areas.

More recent reviews focused on cancer and serious illness tend to describe limited evidence and mixed results, while still acknowledging that some patients report meaningful relief in pain, nausea, appetite changes, sleep and mood symptoms. A 2024 review of medicinal cannabis products in cancer symptom management highlights potential benefits alongside neuropsychiatric adverse effects and drug interactions.

That balance is precisely why “Ryan’s law” debates belong in the health-policy space rather than culture-war talking points. A patient at the end of life is often navigating opioids, anti-nausea drugs, steroids, sleep aids and anxiety medications. Cannabis can add side effects such as dizziness, sedation, anxiety, confusion or cardiovascular effects, and it can interact with other medications. Serious conversations with clinicians remain essential, even when the product is state-legal.

Facility-based access does not remove the need for careful dosing, timing and route selection. Non-inhaled options, including capsules, tinctures and edibles, can fit smoke-free policies, yet they have slower onset and longer duration, which can complicate symptom titration for frail patients.

Arizona already has part of this conversation in law

Arizona patients have lived with the “facility” question for years.

Under Arizona Revised Statutes, certain facilities may not “unreasonably limit” a registered qualifying patient’s access to or use of medical marijuana. Facilities can set reasonable restrictions, including refusing to store a patient’s marijuana, requiring consumption by a method other than smoking, and requiring use only in a place specified by the facility. A facility can impose greater limits if failing to do so would cause the facility to lose a monetary or licensing-related benefit under federal law or regulations.

That framework is familiar to anyone who has tried to coordinate care for an older adult in assisted living or a nursing home. The law recognizes patient access while acknowledging federal pressure points. It also leaves room for uneven implementation, because “reasonable” and “unreasonable” often become matters of policy drafting, staff training and risk tolerance.

Arizona’s gap, much like Hawaii’s, is most visible when the setting shifts into acute care. Hospital policies can be stricter and more variable, which is part of why “Ryan’s law” bills are being filed to clarify expectations. Marijuana Moment reported that an Arizona proposal would add hospitals to the list of facilities where terminally ill qualifying patients could use medical cannabis, subject to facility-designated areas and restrictions.

A bill tracking summary for Arizona’s HB 2081 describes a “Ryan’s law” approach that would require access for terminally ill patients in health care facilities with restrictions similar to those seen in other states, including no smoking or vaping, locked storage and documentation in the medical record.

The parallel is not accidental. Arizona’s existing long-term care protections show that states can craft rules that preserve facility operations while keeping the patient’s legal medicine within reach. Hawaii’s HB 1542 reads like a more prescriptive version of that idea, with explicit instructions on storage, staff roles and admission decisions.

What patients and caregivers can do while laws catch up

“Ryan’s law” efforts often focus on the last mile of access, the point where a patient’s legal status collides with institutional rules. That makes caregivers central to success.

HB 1542 requires the patient or primary caregiver to be responsible for acquiring, administering and removing medical cannabis, and it prevents staff from administering it. That is the pattern patients should plan for even in states with more permissive rules, because most facilities want a bright line between their controlled-substance systems and a patient’s cannabis product.

In practical terms, conversations should start before a crisis admission. Families can ask a facility to provide its written policy, clarify where non-inhaled use is permitted, and determine how products must be stored. Documentation matters. HB 1542 contemplates cannabis use being included in the patient’s medical record. That is an access tool as much as a safety step, because it keeps the care team aware of potential interactions and side effects.

Patients also deserve honest guidance about impairment. Cannabis can affect coordination, judgment and reaction time, and public health authorities continue to warn against driving after use. For patients moving between home, outpatient appointments and inpatient settings, that guidance can become a family safety issue.

Where The Marijuana Doctor fits in, especially for Arizona families

Policy changes create new rights on paper, then patients still have to navigate real-world systems to use them.

The Marijuana Doctor’s role is not to substitute for a hospitalist or an oncologist, and it should never be presented that way. Our role is to help eligible Arizona patients understand how medical cannabis fits within state rules, what forms may be better aligned with facility restrictions, and how to communicate clearly with caregivers and care teams so cannabis use is not hidden or improvised.

That kind of support is especially relevant when the patient is older, seriously ill or relying on others for daily care. Arizona’s facility statute anticipates reasonable restrictions and federal-risk exceptions, which means the details can shift from one location to the next. Patients do better when they understand those moving parts before they are asked to make choices under stress.

The core ethical question Hawaii is putting on the table

Hawaii’s HB 1542 is a technical bill with a humane impulse.

Its definitions and restrictions are there to protect facilities, staff and other patients. Its intent statement is there to protect dignity: the ability of terminally ill patients and certain older adults with chronic disease to safely use medical cannabis within specified health care facilities.

Critics can debate how broad the eligibility should be, whether “shall permit” should become “may permit,” and how smoking bans should be handled. Hawaii’s medical cannabis regulators and the state attorney general’s office raised concerns about inflexibility and federal conflict exposure, while still recognizing the intent to improve access for terminally ill patients.

That back-and-forth is not a distraction. It is the work of building a policy that holds up when real people rely on it.

Arizona’s experience suggests a lesson for lawmakers everywhere: patient access inside care facilities is rarely solved by one sentence in statute. It is solved when law, clinical reality and facility operations align well enough that a patient does not have to choose between receiving care and keeping symptom relief.

“Ryan’s law” is ultimately a test of whether compassion can be operationalized. When states answer that question clearly, patients spend less time negotiating permissions and more time focusing on comfort, presence and the medical care that brought them to the facility in the first place.

***

Marijuana Doctor is your premier destination for seamless medical marijuana licensing. Our compassionate team guides you with expertise, ensuring a smooth process. Discover the therapeutic benefits in a supportive environment that prioritizes your well-being.

Join a community championing alternative healing methods for a healthier life. Choose Marijuana Doctor for personalized, patient-centered care, and step into a revitalized future.